MetaCap

AEON Biopharma Inc. Class A (AEON)

NYSE: AEONHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.123-0.0101 (-7.59%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AEON stock chart

Technical analysis

Key statistics

All statistics
Market cap
$10.35M
EPS (TTM)
-$3.89
52-week range
0.106 – 1.45
Day range
0.1218 – 0.1346
Volume / Avg
1.17M / 7.44M
Beta
—

52-week range

$0.106$1.45

AEON stock today

AEON Biopharma (AEON) closed at $0.123 on Nov 20, down 7.59% (-$0.0101), versus the S&P 500's 3.70% decline. Trading was light, with 1.17M shares changing hands, about 16% of the average daily volume. Shares are 91.5% below their 52-week high of $1.45, set on Feb 23, 2026 and 16.0% above the 52-week low of $0.106, near the bottom of the past year's range.

AEON is down 88.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 85.2%. AEON Biopharma has posted a net loss over the last twelve months (EPS of -$3.89), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About AEON Biopharma

Company profile

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Robert Bancroft
Headquarters
Irvine, CA
Employees
8

Financial highlights

Full financials

AEON Biopharma reported a net loss of $39.2 million, compared with net income of $42.0 million a year earlier. Diluted earnings per share came in at -$3.95, down from $72.93.

AEON Biopharma annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2022FY 2021
Revenue————
Growth————
Net income$-39.22M$42.01M$-52.56M$8.20M
EPS (diluted)$-3.95$72.93$-0.38—

Analyst forecast

Forecast

Consensus (4 analysts)

strong_buy

Avg. price target

$1.82+1379.67%

  • Strong buy 1
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $1.20High $2.10

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.01 vs $-0.10
Surprise
+90.00%

AEON news

All AEON news

AEON Biopharma peers

Health Care sector
AEON peer companies
CompanyPrice% ChgMarket capCompare
ASBPAspire-Lakewood Holdings Inc.7.13-5.44%$10.00Mvs AEON
RADXRadiopharm Theranostics Limited ADR0.6304-9.71%$9.90Mvs AEON
CMMBChemomab Therapeutics Ltd. ADR1.19+4.39%$9.58Mvs AEON
BFRIBiofrontera Inc.0.53-7.02%$9.51Mvs AEON
GDTCCytoMed Therapeutics Limited0.755-2.33%$9.01Mvs AEON
CALCCalciMedica Inc.1.26+7.69%$8.69Mvs AEON
OPTHOptimi Health Corp.1.51-13.71%$8.65Mvs AEON
BIVIBioVie Inc. Class A0.80-12.07%$8.58Mvs AEON

Indexes, lists and sector

AEON Biopharma stock FAQ

What is AEON Biopharma's stock price today?

AEON last traded at $0.123 as of Nov 20, 4:00 PM EST, down 7.59% on the day. Prices are delayed at least 15 minutes.

Does AEON Biopharma pay a dividend?

No. AEON Biopharma does not currently pay a regular cash dividend.

Who is AEON Biopharma's CEO?

Mr. Robert Bancroft is the chief executive officer of AEON Biopharma Inc. Class A, which has about 8 employees.

Has AEON ever split its stock?

Yes. The most recent AEON stock split was a 1-for-72 split on Feb 26, 2025.

What is the AEON 52-week high?

The 52-week high for AEON is $1.45 and the 52-week low is $0.106. The stock is currently 91.5% below its high.

Compare AEON